scispace - formally typeset
C

Claudio Angelini

Researcher at Humanitas University

Publications -  44
Citations -  2570

Claudio Angelini is an academic researcher from Humanitas University. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 14, co-authored 39 publications receiving 1525 citations. Previous affiliations of Claudio Angelini include University of Kiel & University of Milan.

Papers
More filters
Journal ArticleDOI

Genomewide Association Study of Severe Covid-19 with Respiratory Failure.

David Ellinghaus, +145 more
- 17 Jun 2020 - 
TL;DR: A 3p21.31 gene cluster is identified as a genetic susceptibility locus in patients with Covid-19 with respiratory failure and a potential involvement of the ABO blood-group system is confirmed.
Journal ArticleDOI

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.

François-Xavier Lescure, +297 more
- 01 May 2021 - 
TL;DR: In this article, the authors evaluated the safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical(requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.
Journal ArticleDOI

Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy.

Maurizio Cecconi, +14 more
- 20 May 2020 - 
TL;DR: Age; increased respiratory rate; abnormal blood gas parameters and imaging findings; coexisting coronary heart disease; leukocytosis; lymphocytopenia; and several laboratory parameters were significant predictors of clinical deterioration, which could aid early identification and management of patients at risk.
Journal ArticleDOI

Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19.

Enrico Brunetta, +29 more
- 01 Jan 2021 - 
TL;DR: In this paper, the presence and significance of PTX3 in Coronavirus Disease 2019 (COVID-19) was assessed using RNA-sequencing analysis of peripheral blood mononuclear cells, single-cell bioinformatics analysis and immunohistochemistry of lung autopsy samples.
Journal ArticleDOI

Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.

Lorenzo Maria Canziani, +22 more
- 08 Jul 2020 - 
TL;DR: The use of intravenous tocilizumab was not associated with changes in 30-day mortality in patients with COVID-19 severe respiratory impairment and among the secondary outcomes there was less use of invasive ventilation in the tocilIZumab group.